Phase II clinical trial of peptide vaccination with HLA-A2402-restricted KIF20A and VEGFR1 epitope peptides with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancer
Phase 2
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000004641
- Lead Sponsor
- Department of Gastroenterology Juntendo University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients have uncontrollable associated cancer. 2. Patients have uncontrollable severe infectional diseases. 3. Patients have severe trauma. 4. Patients who are treated with steroid or immunotherapy during clinical trial. 5. Pregnancy or lactation. 6. Patients who have non-recovered injury. 7. Patients judged inappropriated by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method